Patents Examined by Claire Kaufman
  • High affinity human antibodies to human angiopoietin-2
    Patent number: 10875911
    Abstract: The present invention provides antibodies that bind to angiopoietin-2 (Ang-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Ang-2. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Ang-2 biological activities including angiogenesis.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: December 29, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Gavin Thurston, Christopher Daly
  • TRAILR2 CDH17 binding molecules for the treatment of cancer
    Patent number: 10858438
    Abstract: This invention relates to binding molecules that bind specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and cadherin-17 (CDH17) and their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of cancer.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: December 8, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Klaus-Peter Kuenkele, Timothy Fenn, Juan Manuel Garcia-Martinez, Jason Ho, Christian Koessl, Saurabh Sen, Vladimir Voynov, Andreas Wernitznig
  • Antibody molecules to PD-L1 and methods of treating cancer
    Patent number: 10851165
    Abstract: Antibody molecules that specifically bind to PD-L1 are disclosed. Combination therapies comprising the anti-PD-L1 antibody molecules are also disclosed. The anti-PD-L1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: December 1, 2020
    Assignees: Novartis AG, Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Gordon James Freeman, Arlene Helen Sharpe, Gerhard Johann Frey, Hwai Wen Chang, Jennifer Marie Mataraza, Glenn Dranoff
  • Antibodies against TL1a and uses thereof
    Patent number: 10822422
    Abstract: The disclosure provides TNF-like ligand 1a (TL1a)-binding proteins comprising an antigen binding domain of an antibody which binds specifically to TL1a and inhibits interaction of TL1a and Death Receptor 3 (DR3) and which does not inhibit the interaction of TL1a and Decoy Receptor 3 (DcR3). The disclosure also provides uses of the TL1a-binding proteins.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: November 3, 2020
    Assignee: Teva Pharmaceuticals Australia Pty Ltd
    Inventors: Lynn Dorothy Poulton, Adam Clarke, Andrew James Pow, Debra Tamvakis, George Kopsidas, Anthony Gerard Doyle, Philip Anthony Jennings, Matthew Pollard
  • Bispecific antibody binding TRAIL-R2 and CD3
    Patent number: 10813995
    Abstract: The present invention concerns the field of cancer immunotherapy, and in particular drugs with low toxicity which can overcome drug-resistance. The present invention concerns novel bispecific antibodies which have the capability of binding both the TRAIL tumor associated antigen and the T lymphocyte CD3. The invention further relates to compositions comprising the bispecific antibodies and a labelling agent, and to pharmaceutical compositions. The present invention also relates to the use of the bispecific antibodies in the treatment of a tumor.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: October 27, 2020
    Assignee: FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI
    Inventors: Mariangela Figini, Alessandro Satta, Alessandro Massimo Gianni, Massimo Di Nicola
  • Methods of treating and/or preventing chronic obstructive pulmonary disease
    Patent number: 10813911
    Abstract: The present invention relates to a novel composition or method of use for the treatment and/or the prevention of chronic obstructive pulmonary disease (COPD) and acute exacerbations of chronic obstructive pulmonary disease (AECOPDs).
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: October 27, 2020
    Inventors: Patrick Berger, Isabelle Dupin, Pierre-Olivier Girodet
  • Macrophages eat cancer cells using their own calreticulin as a guide
    Patent number: 10780117
    Abstract: Therapeutic and diagnostic methods are provided, which methods relate to the induction of expression of calreticulin on phagocytic cells. Specifically, the methods relate to macrophage-mediated programmed cell removal (PrCR), the methods comprising increasing PrCR by contacting a phagocytic cell with a toll-like receptor (TLR) agonist; or down-regulating PrCR by contacting a phagocytic cell with an inhibitor of Bruton's tyrosine kinase (BTK). In some embodiments, an activator of TLR signaling or a BTK agonist is provided in combination with CD47 blockade.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: September 22, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Irving L. Weissman, Mingye Feng, Jens-Peter Volkmer
  • Anti SIRP-? antibodies and bi-specific macrophage enhancing antibodies
    Patent number: 10781256
    Abstract: Anti-SIRP? antibodies, including multi-specific anti-SIRP? antibodies, are provided, as are related compositions and methods. The antibodies of the disclosure bind to SIRP? and can block the interaction of CD47 on one cell with SIRP? on a phagocytic cell. Antibodies that are bispecific for SIRP? and a second antigen are termed Bi-specific Macrophage Enhancing (BiME) antibodies and have emergent properties. The subject anti-SIRP? antibodies find use in various therapeutic methods. Embodiments of the disclosure include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the anti-SIRP? antibodies; and cell lines that produce the antibodies. Also provided are amino acid sequences of exemplary anti-SIRP? antibodies.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: September 22, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Kipp Andrew Weiskopf, Aaron Michael Ring, Jens-Peter Volkmer, Irving L. Weissman, Nan Guo Ring
  • SIRP-gamma polypeptide compositions and methods of use
    Patent number: 10774125
    Abstract: Provided herein are SIRP-gamma, SIRP-beta or SIRP-beta2 decoy polypeptides for immunotherapy and/or treatment of cancer, anemia, transplant, asthma, allergy, auto-immune disease, and viral infection.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: September 15, 2020
    Assignee: AB INITIO BIOTHERAPEUTICS, INC.
    Inventors: Aaron Michael Ring, Roy Louis Maute, Andrew Curtis Kruse, Aashish Manglik, Kenneth S. Lin
  • Natural killer cells modified to express membrane-bound interleukin 15 and uses thereof
    Patent number: 10774311
    Abstract: The present invention provides, in certain aspects, a natural killer (NK) cell that expresses all or a functional portion of interleukin-15 (IL-15), and methods for producing such cells. The invention further provides methods of using a natural killer (NK) cell that expresses all or a functional portion of interleukin-15 (IL-15) to treat cancer in a subject or to enhance expansion and/or survival of NK cells.
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: September 15, 2020
    Assignees: National University of Singapore, St. Jude Children's Research Hospital, Inc.
    Inventors: Dario Campana, David Shook, Masaru Imamura
  • Anti-EGFR antibody and uses of same
    Patent number: 10759860
    Abstract: This disclosure relates generally to an EGFR antibody and its therapeutic effects on tumor inhibition in vitro and in vivo, alone or in combination with various chemotherapeutic agents. In particular, the present disclosure relates to methods for the treatment of cancer, comprising administering an EGFR antibody, alone or in combination with a chemotherapeutic agent.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: September 1, 2020
    Assignee: Synermore Biologics Co., Ltd.
    Inventor: Eric Tsao
  • Anti-CD47 antibody molecules
    Patent number: 10683350
    Abstract: The invention relates to antibody molecules and antigen-binding portions thereof which bind specifically to CD47 (Cluster of Differentiation 47, also known as integrin associated protein [IAP]). In aspects of the invention, the anti-CD47 antibody molecules and antigen-binding portions thereof specifically bind to human CD47 and cynomolgus monkey CD47. Medical uses of the anti-CD47 antibody molecules and antigen-binding portions of the invention are disclosed. The anti-CD47 antibody molecules and antigen-binding portions of the invention represent modified and optimised binding molecules compared with a VxP037 murine/humanized anti-CD47 antibody described in WO2014/093678A2.
    Type: Grant
    Filed: August 19, 2019
    Date of Patent: June 16, 2020
    Assignee: ULTRAHUMAN FOUR LIMITED
    Inventor: William James Jonathan Finlay
  • Use of phosphatidylinositol phosphate-binding material for apoptosis detection
    Patent number: 10684273
    Abstract: The present invention relates to a method for detecting apoptosis using a phosphatidylinositol phosphate-binding material, a method for screening anticancer agents, a method for screening apoptosis-inhibiting materials, and a method for inhibiting phagocytosis.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: June 16, 2020
    Assignees: GIL MEDICAL CENTER, GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Byung Chul Oh, Ok Hee Kim, Cheol Soon Lee
  • Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
    Patent number: 10647774
    Abstract: Anti-DR5 family member antibodies and bispecific antibodies comprising one or more anti-DR5 family member antibodies are disclosed. These antibodies can be used to trigger cell death on DR5 positive cells.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: May 12, 2020
    Assignee: GENMAB B.V.
    Inventors: Claudine Brigitte Fernande Vermot-Desroches, Olivier Frédéric Subiger, Laurence Françoise Jeanne-Marie Bourdin
  • Treatment and reversal of fibrosis and inflammation by inhibition of the TL1A-DR3 signaling pathway
    Patent number: 10633449
    Abstract: The invention relates to methods of treating fibrosis and inflammatory bowel disease. In one embodiment, the present invention treats gut inflammation by administering a therapeutically effective dosage of TL1A inhibitors and/or DR3 inhibitors to an individual. In another embodiment, the present invention provides a method of reversing tissue fibrosis in an individual by inhibiting TL1A-DR3 signaling function.
    Type: Grant
    Filed: March 27, 2014
    Date of Patent: April 28, 2020
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventors: David Q. Shih, Stephan R. Targan, Dalin Li, Janine Bilsborough
  • SIRP-? agonist antibody
    Patent number: 10618976
    Abstract: Compositions and methods are provided relating to anti-SIRP? agonist antibodies. The antibodies of the invention bind to human SIRP?, and activate signaling, thereby inhibiting processes mediated by SIRP?, including without limitation phagocytosis. Embodiments of the invention include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the anti-SIRP? agonist antibodies; and cell lines that produce these antibodies.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: April 14, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Irving L. Weissman, Benson George, Nan Guo Ring, Aaron Michael Ring, Jens-Peter Volkmer
  • Method and compositions for producing disulfide-linked trimeric TNF family of cytokines and their use
    Patent number: 10618949
    Abstract: Compositions of TNF family of cytokines in covalently linked trimeric forms are disclosed. The resulting fusion proteins are secreted as disulfide bond-linked homotrimers, which are more stable in structure and therapeutically more efficacious than their native counterparts.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: April 14, 2020
    Inventor: Peng Liang
  • EGFRvIII antibody and composition comprising same
    Patent number: 10597457
    Abstract: The present disclosure relates to an antibody specifically binding to epidermal growth factor receptor variant III (EGFRvIII), to nucleic acid coding the antibody, to a vector comprising the nucleic acid, to a host cell, to a preparation method of the antibody, and to a pharmaceutical composition comprising the antibody as an active ingredient for treating a cancer or a tumor.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: March 24, 2020
    Assignee: PHARMABCINE INC.
    Inventors: Jae Bong Yoon, Jinsang Yoo, Jin-San Yoo, Weon Sup Lee, Sung-Woo Kim, Sang Ryeol Shim, Sang Soon Byun, Youngae Lee, Hyuk Joon Lee, Do-yun Kim, Jinhee Choi
  • Anti-Dkk-1-anti-RANKL bispecific antibody compounds
    Patent number: 10584174
    Abstract: Bispecific antibody compounds, and methods of using same, are provided which bind and neutralize Dkk-1 and RANKL and which are useful as adjuncts to spinal fusion surgery or as agents for bone healing or treating conditions associated with bone loss or degeneration.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: March 10, 2020
    Assignee: Eli Lilly and Company
    Inventors: Victor H Obungu, Andrew Korytko
  • Antibody constructs for EGFRVIII and CD3
    Patent number: 10519241
    Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human EGFRVIII on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: December 31, 2019
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Tobias Raum, Ines Herrmann, Patrick Hoffmann, Peter Kufer, Markus Muenz, Doris Rau